0R

Naturhouse Health SALSE Naturhouse Stock Report

Last reporting period 30 Jun, 2024

Updated 21 Oct, 2024

Last price

Market cap $B

0.325

Micro

Exchange

XLON - London Stock Exchange

0R9G.L Stock Analysis

0R

Avoid

Based on Eyestock quantitative analysis, 0R9G.L`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

122/100

High score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-19.6 %

Greatly overvalued

Market cap $B

0.325

Dividend yield

16.36 %

Shares outstanding

59.949 B

Naturhouse Health SA engages in the exportation, wholesale and retail sale of products related to dietetics, medicinal herbs and natural cosmetics. The company is headquartered in Madrid, Madrid and currently employs 208 full-time employees. The company went IPO on 2015-04-09. The firm specializes in developing, manufacturing and selling products within the nutrition, as well as weight management sector. Its activities are divided into three business areas: Food Supplements, which provides products with natural extracts to facilitate the slimming process; Healthy Foods and Drinks, which offers dietary snacks and meals for breakfast; as well as Cosmetics and Body Care, which includes cosmetics for skin treatment during the slimming process. The firm distributes products through a network of own and franchised stores. Furthermore, It operates in Spain, France, Poland, Italy, Mexico, the United Kingdom, and Canada, among others. The firm is a subsidiary of Kiluva SA, as well as controls a number of entities, such as SAS Naturhouse, Kiluva Diet SLU, Zamodiet Mexico SA de CV and Naturhouse Sp z o o.

View Section: Eyestock Rating